The Truth Gender Clinicians Tried to Ignore - Dr Susan Bradley (#43)
16 October 2025
With Dr. Susan Bradley
North America
Dr. Susan Bradley co-founded North America's first paediatric gender clinic in 1975, sat on the DSM-IV committee, and treated more than four hundred gender-dysphoric children. In this episode she documents what the evidence actually showed across fifty years: high childhood desistance rates, a near-inevitable escalation from puberty blockers to hormones, an under-acknowledged autism link, and the institutional silencing of clinicians who reported what they observed.
Dr. Susan Bradley co-founded the gender identity clinic at Toronto's Centre for Addiction and Mental Health in 1975, treated more than four hundred gender-dysphoric children across nearly five decades of practice, and chaired the DSM-IV subcommittee on gender identity disorders. When a clinician with that record speaks critically about where the field has gone, the professional weight behind the account is considerable. The central finding from her clinical experience is one documented in the research literature for decades but largely set aside in practice: most children presenting with gender dysphoria do not grow up to be transgender adults. In Bradley's cohort, even those deeply convinced of a cross-sex identity were nearly all gay or lesbian by adulthood. This pattern — clinical desistance — underpinned the long-term follow-up studies produced by Bradley, Ken Zucker and their colleagues at CAMH, and whether affirmation-only pathways foreclose this developmental trajectory is now a central question in European evidence reviews. On puberty blockers, Bradley is unequivocal: she does not believe they are reversible. The Dutch protocol that introduced them and the endocrinologists who promoted them characterised blockers as a neutral pause preserving future options. The follow-up data has not supported that characterisation. Once young people begin puberty suppression, approximately ninety percent proceed to cross-sex hormones — a progression rate more consistent with a one-directional clinical pipeline than an open decision point. This specific concern is now addressed in the Cass Review and in revised clinical guidelines issued by Sweden, Finland, Denmark and Norway. Bradley also addresses elevated autism rates in gender-dysphoric populations — research she cites puts the prevalence at three to six times that of the general population. Autistic young people may process identity and solutions to distress in ways that standard gender-medicine protocols did not account for. Multiple European reviews have flagged this co-occurrence as requiring specialist assessment rather than a default affirmation pathway. The episode gives considerable attention to the suppression of clinical dissent. Bradley's long-time colleague Ken Zucker — whose research underpins much of the desistance evidence — was dismissed from CAMH in 2015 following an activist campaign that characterised his therapeutic work as conversion therapy. CAMH subsequently issued an apology and reached a financial settlement with him. The chilling effect on clinicians willing to follow the evidence rather than prevailing ideology bears directly on current European debates: conversion-therapy legislation under consideration or already enacted in several jurisdictions risks inadvertently prohibiting the kind of exploratory psychotherapy that Bradley and Zucker practised, and that a growing body of evidence now suggests should have been standard care all along. Bradley is not delivering a settled historical account. She is describing what clinical evidence showed across fifty years, what the field chose not to hear, and what has followed from that refusal. The institutional mechanisms she identifies — the suppression of follow-up research, the pipeline disguised as watchful waiting, the professional retaliation against dissenters — are the same ones now being examined in systematic reviews and legislative proceedings across Europe.
